Labcorp won the first FDA approval for a non-prescription multi-analyte COVID-19 test, plus four more updates on the lab company since March:
1. Labcorp is offering a new test designed to detect and quantify unintentional gluten consumption. The company said it is the first U.S. commercial lab to offer the test, which was developed by Immundiagnostik. It detects gluten in a patient's stool sample.
2. Labcorp and Atlantic City, N.J.-based AtlantiCare expanded an existing long-term partnership. Under the new deal, Labcorp is acquiring assets from AtlantiCare's clinical outreach business and will operate some AtlantiCare physician office phlebotomy sites and outpatient collection services. AtlantiCare's patients will have access to Labcorp's test menu and services through the company's network of patient service centers.
3. Labcorp launched a first-of-its-kind, at-home diabetes risk testing kit. Labcorp is the only commercial lab to offer Weavr Health's Velvet blood collection device, which is part of the testing kit and is available through Labcorp OnDemand.
4. The FDA approved a Labcorp COVID-19, flu and respiratory syncytial virus test for use without a prescription. The test is the first non-prescription multi-analyte COVID-19 test the FDA has authorized. The test involves an at-home nasal swab that is sent to Labcorp for analysis. Individuals can see their results on an online portal.
5. Former Labcorp CEO and chair Dave King joined PathGroup's board as chair, as part of an investment partnership with private equity firm GTCR.